Introduction {#sec1-1}
============

Lung cancer is the most common cancer killer worldwide, with a five-year survival rate of only 15% (Jemal et al., 2009). In the United States, there are approximately 226,000 new cases annually with an estimated 160,000 deaths (Siegel et al., 2012), and it cost an estimated US\$ 12 billion in 2010 (Mariotto et al., 2011). Non-small cell lung carcinoma (NSCLC) is one of two major types of lung cancer which accounts for 80--90% of all lung cancer cases (Siegel et al., 2014). Researches on the survival rate of these patients aim at identification of influential demographic and clinical factors. Rapp et al., (1988) evaluated the patients with NSCLC and showed that their median survival is about 4-5 months, with one-year survival rate of only 10%. Another similar study showed high mortality of these people, with an average survival of 7.150 months (Wao et al., 2013). A research in Germany in 2013 on 285 patients with lung cancer concluded that quitting smoking increases the efficacy of treatment and improves their quality of life (Andreas et al., 2013). In a study in the Netherlands on 451 patients with NSCLC who underwent surgery, they found that surgery greatly reduces mortality rates (Battafarano et al., 2002). A study on the effect of sex on survival of patients with NSCLC who underwent surgery in Canada revealed that female gender can be a favorable factor for a better survival in stage one (Noris et al., 2013). Efficiency and validity of assessment tools are very important. Statistical methods for survival analysis are efficient instruments in identifying effective factors.

Studies have been conducted to compare parametric models and semi-parametric models in survival data analysis. Cox proportional hazards model (as a semi-parametric method), accelerated failure time (AFT) models such as Weibull, exponential, log-normal, and logistic-log (as parametric methods) and non-parametric Kaplan-Meier method are the most important approaches to analyze survival data. Various studies have been conducted on different clinical datasets to investigate the efficiency of different models. According to the results of these studies, different models do not have similar efficiency on different clinical data so that different data analyses require exploration among different models to find more efficient models. In a simulation study, it was shown that log-normal models and logistic logic models are more efficient than Cox model (Orbe et al., 2002). So far, the studies on patients with NSCLC have been done with semi-parametric method. Therefore, conducting a study using both parametric and semi-parametric methods, in addition to determining risk factors, may lead to the introduction of a more efficient model. The purpose of the present study was to find the survival rate of patients with NSCLC, to determine prognostic factors which improve the survival rate (with the fitness of parametric and semi-parametric models) and finally, to select the best model to analyze survival.

Materials and Methods {#sec1-2}
=====================

In a retrospective cohort study during the period 2005 to 2014, totally 200 records with NSCLC were extracted, 190 patients of whom were eligible to enter the study. These patients had visited Shahid Sadoughi and Shohadaye Kargar hospitals in Yazd, Iran. Data were collected from medical records of the patients, and completed with the latest health status of patients asked by telephone. The recorded demographic and clinical variables included age (23-65 or 66-91 years), the type of treatment (either surgery, chemotherapy or chemotherapy plus radiotherapy), the stage of the cancer at diagnosis (II, III or IV), history of smoking, duration of smoking, gender, histopathologic type (adenocarcinoma, squamous cell carcinoma \[SCC\], or large cell carcinoma \[LCC\]), patients' place of residence (the city of Yazd, other locations within the province of Yazd, or cities in other provinces), occurrence of death, the length of time between diagnosis and the commencement of treatment (in months), and the length of time between diagnosis and death (in months). To determine the survival rate, Kaplan-Meier non-parametric test was used. Also, univariate tests were done using log rank test to identify effective (significant) factors in survival rate. Then, for comparison of the multivariate parametric and Cox semi-parametric models, Akaike information criterion (AIC), the most efficient model was selected to determine influential factors. AIC is a measure of the goodness of fit in which each model with a smaller value is the proposed model which fits the data well. All of the analyses in this study were performed using the software R3.3.1, and all tests were carried out two-sided. P-values less than 0.05 were assumed significant.

Results {#sec1-3}
=======

Among 190 patients in this retrospective cohort, their median age was 64.500 years. Males constituted 71.600% of them (136 patient), and 76 (40%) of the patients were in stage IV at the time of diagnosis. Treatment methods undertaken were surgery alone in 53 patients (27.900%), chemotherapy alone in 66 patients (34.700%), and chemotherapy plus radiotherapy in 71 patients (37.400%). Results of evaluation of the survival rate at each level of variables that became significant in univariate log rank test are shown in [Table 1](#T1){ref-type="table"}.

###### 

Demographic Characteristics of Patients with Non-Small Cell Lung Carcinoma and Results of Log Rank Test

  Variable                                   n (percent)       p-value
  ------------------------------------------ ----------------- ---------
  Age (year)                                                   0.001
   23-65                                     101.00 (53.200)   
   66-91                                     89.00 (46.800)    
  Type of treatment                                            0
   Surgery                                   53.00 (27.900)    
   Chemotherapy                              66.00 (34.700)    
   Chemotherapy plus radiotherapy            71.00 (37.400)    
  Stage of the disease                                         0
   I                                         58.00 (30.500)    
   III                                       56.00 (29.500)    
   IV                                        40.00 (76.000)    
  History of smoking                                           0.323
   Yes                                       110.00 (57.900)   
   No                                        80.00 (42.100)    
  Duration of smoking                                          0.544
   0                                         80.00 (42.100)    
   \<1year                                   50.00 (26.300)    
   ≥1year                                    60.00 (31.600)    
  Gender                                                       0.264
   Man                                       136.00 (71.600)   
   Woman                                     54.00 (28.400)    
  Histopathologyic subtype                                     0.107
   Adenocarcinoma                            77.00 (44.500)    
   Squamous cell carcinoma                   55.00 (28.900)    
   Large cell carcinoma                      58.00 (30.500)    
  Place of residence                                           0.364
   City of Yazd                              91.00 (47.900)    
   Other locations in the province of Yazd   34.00 (17.900)    
   Cities in other provinces                 65.00 (34.200)    

The median survival of the patients was 8 months (range 1-48 months) ([Figure 1](#F1){ref-type="fig"}).
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The 6-months survival rate for each of the age groups was as follows: 0.689 for the group 23-65 years (with standard error, SE= 0.047 and confidence interval, CI=0.603-0.788); 0.543 for the group 66-91 years (with SE= 0.053 and CI=0.448-0.658). The 18-months survival rates for the two age groups were 0.222 and 0.097, respectively. The 6-months survival rate for each type of treatment modalities were as follows: 0.140 for surgery (with SE=0.052 and CI=0.068-0.288); 0.576 for chemotherapy (with SE=0.062 and CI=0.467-0.712); and 0.986 for chemotherapy plus radiotherapy (with SE=0.014 and CI=0.959-1). The 18-months survival rates for the above-mentioned treatment groups were 0.037, 0.055 and 0.323, respectively. The 6-months survival rates for each of the clinical stages of the disease were as follows: 0.860 at stage II (with SE= 0.046 and CI=0.775-0.955); 0.784 at stage III (with SE= 0.055 and CI=0.683-0.900); 0.298 at stage IV (with SE=0.055 and CI=0.208-0.428). The 18-months survival rates for the stage II, III and IV were 0.308, 0.177 and 0.020, respectively.

Multivariate models of Cox, exponential, Weibull, log-normal, and logistic log were used for final modeling and comparison of the efficiency of models in predicting significant factors. Multivariate models are reported in [Table 2](#T2){ref-type="table"}.

###### 

Multivariate Analysis of Prognostic Factors with Cox and Parametric Models

                         Cox                                             Exponential RR (SE)                             Weibull                                         Log-Normal                                      Logistic log RR (SE)
  ---------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Stage of the disease   2.519 (0.117)[\*](#t2f1){ref-type="table-fn"}   1.425 (0.098)[\*](#t2f1){ref-type="table-fn"}   1.494 (0.044)[\*](#t2f1){ref-type="table-fn"}   1.344 (0.045)[\*](#t2f1){ref-type="table-fn"}   0.744 (0.036)[\*](#t2f1){ref-type="table-fn"}
  Type of treatment      0.286 (0.116)[\*](#t2f1){ref-type="table-fn"}   0.547 (0.103)[\*](#t2f1){ref-type="table-fn"}   0.578 (0.045)[\*](#t2f1){ref-type="table-fn"}   0.510 (0.048)[\*](#t2f1){ref-type="table-fn"}   1.879 (0.040)[\*](#t2f1){ref-type="table-fn"}
  Age                    1.580 (0.167)[\*](#t2f1){ref-type="table-fn"}   1.336 (0.162)                                   1.234 (0.074)[\*](#t2f1){ref-type="table-fn"}   1.203 (0.074)[\*](#t2f1){ref-type="table-fn"}   0.912 (0.058)
  AIC                    1207.588                                        1036.422                                        911.059                                         889.383                                         971.996

Significant difference at 0.05; HR, hazard ratio; RR, relative risk; SE, standard error; AIC, Akaike information criterion.

Stage of the disease and the type of treatment had significant relationships with patients' survival at p\<0.05 Also, age was significant in all models, except in exponential and logistic log models. Also, according to the reported AIC values, log-normal model with the minimum value (AIC=889.383) showed better fitness. Therefore, the results of log-normal model for analysis at different levels of factors that influence survival rates are reported as is seen in [Table 3](#T3){ref-type="table"}. Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"} show log-normal plots of the survival by influential factors.

###### 

Multiple Log- Normal Model Classification

  ----------------------------------------------------------------------------
  Variable                          coef.    RR\     LCL\    UCL\    p-value
                                             (HR)    95%     95%     
  --------------------------------- -------- ------- ------- ------- ---------
  Stage of the disease                                               

   II                               Ref                              

   III                              -0.282   1.325   1.101   1.595   \<0.010

   IV                               -0.6     1.823   1.525   2.178   \<0.010

  Type of treatment                                                  

   Surgery                          Ref                              

   Chemotherapy                     0.754    0.47    0.391   0.566   \<0.010

   Chemotherapy plus radiotherapy   1.352    0.259   0.214   0.312   \<0.010

  Age                                                                

   23-65                            Ref                              

   66-91                            -0.173   1.189   1.028   1.375   0.02
  ----------------------------------------------------------------------------

RR, relative risk; HR, hazard ratio; LCL, lower confidence limit; UCL, upper confidence limit; Ref, reference
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The hazard ratios (HR) divide the death rate in patients with the characteristic by the death rate in patients without the characteristic (reference group) as a measure of relative risk, according to the reported relative risk of patients in Stage III showed the risk of death in Stage III is 1.325 times higher than risk of death in Stage II (reference group).

Discussion {#sec1-4}
==========

The present study was conducted to determine the survival of patients with non-small cell lung carcinoma, to find prognostic factors of survival, and to determine the most efficient model for analysis of survival among parametric and non-parametric models. Stage of the disease, the type of treatment and age were identified by log-normal test as significant elements which affect survival. Multivariate analyses of Cox, Weibull, exponential, log-normal, and logistic log models were fitted on the data. Finally, log-normal model was selected as the most efficient model using Akaike's information criteria.

There are different views on the most efficient model in prediction of survival and its determinants in patients with cancer. In a study conducted to compare Cox model vs. parametric models on 197 children with acute leukemia in Iran, it was indicated that parametric models are preferred, and the Weibull method is the most efficient model among them (Hosseini Teshnizi and Ayatollahi, 2017). In another study that compared Cox model and parametric models on 484 patients with gastrointestinal cancer, parametric models were found preferred, and logistic log model was the most efficient model (Ghadimi et al., 2011). In again another work on comparison of Cox model vs. parametric models in 3421 patients, the findings showed that parametric models are the best, and gamma model was the most efficient model among the latter (Ravangard et al., 2011). Still another study conducted on 408 patients with gastric cancer to compare Cox model and parametric models, parametric models were preferred, especially Weibull model (Roshanaei et al., 2011). Among non-neoplastic diseases, a study on 529 patients with liver transplant showed that parametric models were performing better than Cox model, and log-normal model was the most efficient model among parametric models (Adelian et al., 2015). In a study carried out in Ireland by Ramzi et al., (2012) on 292 patients, they stated that modern chemotherapy can have positive effects on survival of patients with NSCLC who have poor performance. Chinese researchers studied 221 operated patients with NSCLC in 2012, and stated that postoperative radiotherapy can significantly improve the survival rate of the patients, which is consistent with our study (Dai et al., 2011). Hsu et al., (2012) studied patients 45 years of age and younger with NSCLC; there was a significant relationship between survival and stage of the disease. They deduced that stage IV is a negative influential factor. A direct relationship between age and survival and also between histological grade and survival was found in a research carried out in China on prognostic factors influencing the survival of patients with NSCLC; that is, old age and poor histological differentiation were associated with poor survival, the former being similar to the results of our study (Wang et al., 2011). A study in Brazil found that survival in NSCLC patients is independent of gender and histologic type (Santoro et al., 2011). All of the results of the above-mentioned studies are consistent with our findings.

However, there are yet other studies that have yielded findings inconsistent with the present study. In a study performed in the United States they found that there is inverse relationship between the quantity of cigarette smoking in patients with NSCLC and their survival rate after diagnosis (Janjigian et al., 2010). However, in our study the survival of patients was independent of the quantity of tobacco smoking. In a study in Norway they stated that in general, women have a better chance of survival, and this factor is independent of age, treatment modality, histologic type and number of years after diagnosis (Pitz et al., 2013). In Taiwan a similar conclusion was stated by those who studied survival of patients 45 years of age and younger with NSCLC (Hsu et al., 2012). Both of the above studies are inconsistent with our study in which there was a significant relationship between survival and gender. For reasons such as lack of environmental conditions or proper facilities, evaluation of some factors was not possible in our work, which could potentially lead to interesting results: 1) skin color, as was shown in the United States when the researchers studied patients with NSCLC (Shirvani et al., 2012); 2) blood group, according to Sun et al., (2015) in Taiwan who studied 339,432 individuals, among them 1,235 patients had lung cancer, and concluded that the blood group can be influential.

In conclusion, overall, we concluded that according to reported AIC values the most efficient model is log-normal (parametric) model; the age group, the clinical stage of the disease, and the type of treatment of the individual are the most influential predictive factors regarding survival of patients with NSCLC. Identifying these important influential factors on the survival of patients could help in better management. In terms of survival rate, the best type of treatment, provided that all other variables were constant, was chemotherapy plus radiotherapy. The higher the clinical stage of the disease, the lower their survival rate. Also, the age had inverse relationship with the survival rate. Therefore, early diagnosis in younger ages and also a proper method of therapy for patients can reduce the risk of death.
